This Article Full Text Full Text (PDF) All Versions of this Article: 2005-0048OCv1 34/1/92    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Todorova, L. Articles by Westergren-Thorsson, G. Search for Related Content PubMed PubMed Citation Articles by Todorova, L. Articles by Westergren-Thorsson, G.

Lung Fibroblast Proteoglycan Production Induced by Serum Is Inhibited by Budesonide and Formoterol

Department of Cell and Molecular Biology, Lund University; and AstraZeneca R&D Lund, Lund, Sweden

Correspondence and requests for reprints should be addressed to Lizbet Todorova, Division of Vascular and Airway Research, Department of Experimental Medical Science, C13, BMC, Lund University, S-221 84 Lund, Sweden. E-mail: lizbet.todorova{at}med.lu.se

Proteoglycans contribute to extracellular matrix remodeling in asthmatic airways. We investigated the effects of budesonide, a glucocorticoid, and formoterol, a long-acting ₂-adrenergic agonist, on serum-induced proteoglycan production by human lung fibroblasts. In 10% serum, total proteoglycan production was increased 1.5-fold (P < 0.01) compared with basal production in 0.4% serum. Budesonide (10^–8 M) reduced this increase by 44% (P < 0.01) and, whereas formoterol (10^–10–10^–8 M) had no inhibitory effects, the drug combination abolished the increase (P < 0.01) without affecting fibroblast proliferation. This synergistic effect required functional glucocorticoid and -adrenergic receptors. The production of the proteoglycans decorin, biglycan, perlecan, and versican was increased 2.5- to 5-fold (P < 0.01) in 10% serum. Combination treatment with budesonide (10^–8 M) and formoterol (10^–10 M) abolished this increase to a significantly greater extent than either drug alone. In 10% serum, only versican mRNA was increased 1.4-fold (P < 0.05), whereas decorin mRNA was reduced to 39% (P < 0.01) of basal expression. These serum effects were counteracted by the drug combination, but there were no significant differences between the combination and either drug alone. Thus, the budesonide and formoterol combination seems to synergistically control serum-induced proteoglycan production, primarily at the post-transcriptional level. In conclusion, the proteoglycan upregulation characteristic of asthmatic airways may be limited by combination therapy with budesonide and formoterol.

Key Words: lung fibroblasts • airway remodeling • proteoglycans • glucocorticoids • ₂-agonists

This article has been cited by other articles:

				J. L. Black, B. G. G. Oliver, and M. Roth Molecular Mechanisms of Combination Therapy With Inhaled Corticosteroids and Long-Acting {beta}-Agonists Chest, October 1, 2009; 136(4): 1095 - 1100. [Abstract] [Full Text] [PDF]

				L. Pini, Q. Hamid, J. Shannon, L. Lemelin, R. Olivenstein, P. Ernst, C. Lemiere, J. G. Martin, and M. S. Ludwig Differences in proteoglycan deposition in the airways of moderate and severe asthmatics Eur. Respir. J., January 1, 2007; 29(1): 71 - 77. [Abstract] [Full Text] [PDF]